Journal
CANCER DISCOVERY
Volume 11, Issue 11, Pages 2674-2676Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-21-1046
Keywords
-
Categories
Ask authors/readers for more resources
The combination of CAR T cells with Pembrolizumab demonstrates efficacy in cold solid tumors with low genomic heterogeneity, while Atezolizumab-Bevacizumab combination offers a straightforward approach of antiangiogenics and immunotherapy for orphan diseases.
Chimeric antigen receptor (CAR) T cells targeting mesothelin plus pembrolizumab, and atezolizumab plus bevacizumab, have recently shown clinical efficacy in phase I trials in malignant pleural and peritoneal mesothelioma. Despite being tested in a highly selected patient population and requiring a complex engineering that can hardly be upscaled, CAR T cells combined with pembrolizumab bring the first proof of efficacy in cold solid tumors with low genomic heterogeneity, while atezolizumab-bevacizumab offers an easy-to-use combination of antiangiogenics and immunotherapy in an orphan disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available